Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Soleno Therapeutics DCCR Securities Lawsuits
Business securities lawsuit

Soleno Therapeutics DCCR Securities Lawsuits

Analysis based on 83 articles · First reported Apr 01, 2026 · Last updated May 05, 2026

Sentiment
-70
Attention
6
Articles
83
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The multiple class action lawsuits against MiNK Therapeutics, alleging securities fraud and misleading statements regarding its drug DCCR's safety and commercial viability, have led to significant investor losses and a sharp decline in MiNK Therapeutics' stock price. This event highlights the increased scrutiny on biotechnology companies' clinical trial disclosures and the potential for legal and reputational fallout from adverse drug safety reports.

Biotechnology Legal Services
Event Summary

Multiple investor-rights law firms, including The Schall Law Firm, Faruqi & Faruqi, Bronstein, Gewirtz & Grossman, LLC, The Law Offices of Frank R. Cruz, Rosen Law Firm, and Pomerantz LLP, have filed class action lawsuits against MiNK Therapeutics. These lawsuits allege that MiNK Therapeutics made false and misleading statements to investors between March 26, 2025, and November 4, 2025, regarding its drug candidate, diazoxide choline extended-release tablets (DCCR), for treating hyperphagia in individuals with Prader-Willi syndrome (PWS). The complaints claim that MiNK Therapeutics systematically downplayed or concealed significant safety concerns, including excess fluid retention and a patient death, and misrepresented DCCR's commercial viability. A critical report by Scorpion Capital on August 15, 2025, a subsequent disclosure of a patient death on September 10, 2025, and MiNK Therapeutics' Q3 2025 financial results on November 4, 2025, which revealed disruptions to DCCR's launch and increased discontinuations, all contributed to substantial declines in MiNK Therapeutics' stock price. Investors are encouraged to join the class actions before the May 5, 2026, lead plaintiff deadline.

Key Actions
100 The Schall Law Firm filed class action lawsuit MiNK Therapeutics
95 Faruqi & Faruqi investigating claims MiNK Therapeutics
95 Kahn Swick & Foti notifies investors of lawsuit MiNK Therapeutics
90 MiNK Therapeutics filed Form 8-K United States — United States Securities and Exchange Commission
90 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit MiNK Therapeutics
90 Pomerantz LLP filed lawsuit MiNK Therapeutics
90 MiNK Therapeutics reported financial results
86 MiNK Therapeutics made misleading statements
85 MiNK Therapeutics reported financial results
85 The Law Offices of Frank R. Cruz filed lawsuit MiNK Therapeutics
82 Scorpion Capital issued report MiNK Therapeutics
80 Hagens Berman notified investors
75 Rosen Law Firm filed class action lawsuit MiNK Therapeutics
Entities Involved
stock
MiNK Therapeutics
MiNK Therapeutics is the primary defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about the safety and commercial viability of its drug candidate, DCCR. The company's stock price has significantly declined following reports of safety concerns, a patient death, and disruptions in DCCR's launch.
Importance 100 Sentiment -85
priv
Scorpion Capital
Scorpion Capital published a critical report on MiNK Therapeutics' drug candidate DCCR, alleging significant concerns regarding its safety, efficacy, and clinical trial data, which led to a decline in MiNK Therapeutics' stock price.
Importance 90 Sentiment 80
priv
Kahn Swick & Foti
Kahn Swick & Foti is the law firm initiating and representing investors in the class action securities lawsuit against MiNK Therapeutics, seeking to recover losses on behalf of affected investors.
Importance 80 Sentiment 20
priv
The Schall Law Firm
The Schall Law Firm is actively representing investors in a class action lawsuit against MiNK Therapeutics, alleging violations of federal securities laws.
Importance 70 Sentiment 50
priv
Faruqi & Faruqi
Faruqi & Faruqi is investigating potential claims against MiNK Therapeutics and reminds investors of the lead plaintiff deadline in the federal securities class action.
Importance 70 Sentiment 50
priv
Rosen Law Firm
Rosen Law Firm is a global investor rights law firm reminding purchasers of MiNK Therapeutics common stock about the lead plaintiff deadline for the class action lawsuit.
Importance 70 Sentiment 50
priv
Hagens Berman
Hagens Berman is a national shareholder rights law firm that is representing investors in the securities class action against MiNK Therapeutics.
Importance 70 Sentiment 50
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized investor-rights law firm that has filed a class action lawsuit against MiNK Therapeutics and its officers.
Importance 65 Sentiment 50
priv
Pomerantz LLP
Pomerantz LLP has announced a class action lawsuit against MiNK Therapeutics, advising investors to contact them regarding potential securities fraud.
Importance 65 Sentiment 50
priv
The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is representing investors in a securities fraud lawsuit against MiNK Therapeutics, alleging misleading statements about its drug candidate DCCR.
Importance 60 Sentiment 50
per
Lewis Kahn
Lewis Kahn, Managing Partner at Kahn Swick & Foti, is a key contact for investors interested in joining the class action lawsuit against MiNK Therapeutics.
Importance 40 Sentiment 10
govactor
United States — United States Securities and Exchange Commission
The United States — United States Securities and Exchange Commission is the regulatory body under whose rules MiNK Therapeutics filed a Form 8-K and whose regulations are cited in the class action lawsuits.
Importance 30 Sentiment 0
per
Charles Foti
Charles Foti, former Attorney General of Louisiana, is a partner at Kahn Swick & Foti, the law firm handling the class action lawsuit against MiNK Therapeutics.
Importance 30 Sentiment 10
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is mentioned as a key figure in the firm's success in securities class actions.
Importance 30 Sentiment 50
per
Reed Kathrein
Reed Kathrein is a partner at Hagens Berman leading the firm's investigation into the alleged claims against MiNK Therapeutics.
Importance 30 Sentiment 20
+ 7 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.